Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Gains from Investment Securities (2021 - 2024)

Kezar Life Sciences' Gains from Investment Securities history spans 4 years, with the latest figure at -$8000.0 for Q4 2024.

  • For Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$8000.0; the TTM value through Dec 2024 reached $16000.0, down 94.56%, while the annual FY2024 figure was -$8000.0, 100.61% down from the prior year.
  • Gains from Investment Securities for Q4 2024 was -$8000.0 at Kezar Life Sciences, down from $1.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.9 million in Q4 2021 and bottomed at -$8000.0 in Q4 2022.
  • The 4-year median for Gains from Investment Securities is $700000.0 (2022), against an average of $1.8 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 100.12% in 2022 before it skyrocketed 5713.06% in 2024.
  • A 4-year view of Gains from Investment Securities shows it stood at $6.9 million in 2021, then tumbled by 100.12% to -$8000.0 in 2022, then soared by 12425.28% to $986022.0 in 2023, then tumbled by 100.81% to -$8000.0 in 2024.
  • Per Business Quant, the three most recent readings for KZR's Gains from Investment Securities are -$8000.0 (Q4 2024), $1.4 million (Q2 2024), and $986022.0 (Q3 2023).